Showing results (231-240 of 346) with videos related to

Sort By:
Pageof 35
Cancer|September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
American Journal of Hematology|February 5, 2024
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II studySairah Ahmed, Qaiser Bashir, Roland L Bassett, et al.
British Journal of Haematology|June 28, 2023
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplantOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
American Journal of Hematology|July 18, 2023
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experienceOren Pasvolsky, Denái R Milton, Adeel Masood, et al.
British Journal of Haematology|October 23, 2015
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Transplantation and Cellular Therapy|December 5, 2022
HLA Factors versus Non-HLA Factors for Haploidentical Donor SelectionRohtesh S Mehta, Kai Cao, Rima M Saliba, et al.
Bone Marrow Transplantation|January 5, 2021
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHDRohtesh S Mehta, Roland Bassett, Gabriela Rondon, et al.
British Journal of Haematology|March 6, 2024
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantationKamal Alzahrani, Oren Pasvolsky, Zhongya Wang, et al.
American Journal of Hematology|February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trialIssa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Blood Cancer Journal|May 17, 2024
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationOren Pasvolsky, Zhongya Wang, Denái R Milton, et al.
Pageof 35